Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 3/2020

01-06-2020 | Etanercept | Therapy in Practice

Pharmacological Management of Pediatric Pustular Psoriasis

Authors: Yi-Wei Huang, Tsen-Fang Tsai

Published in: Pediatric Drugs | Issue 3/2020

Login to get access

Abstract

Therapeutic management of pustular psoriasis remains a challenge despite the rapid advance in psoriasis research and the development of drugs, especially biologics. Treatment guidelines have been established for pustular psoriasis, but no controlled studies are present for juvenile pustular psoriasis (JPP). Search of the literature reveals that current evidence of JPP treatment is limited to case reports and case series. Among the conventional drugs for JPP, oral retinoid is the most commonly used, yet concerns for growth disturbance exist. Cyclosporine and methotrexate have also been administered as first-line treatment. Etanercept is the first biological agent approved for juvenile plaque psoriasis, followed by adalimumab. However, infliximab is usually recommended for JPP because of the rapidity of onset, despite not being approved for use in pediatric psoriasis patients. More recently, secukinumab, ixekizumab, brodalumab, guselkumab, and risankizumab have been approved for adult pustular psoriasis in selected countries. Controlled studies are needed to prove the efficacy and long-term safety of the therapeutic treatments currently used for JPP.
Literature
1.
Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R. The epidemiology of childhood psoriasis: a scoping review. Br J Dermatol. 2016;174(6):1242–57.PubMedCrossRef
2.
Lau BW, Lim DZ, Capon F, Barker JN, Choon SE. Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2017;56(4):392–9.PubMedCrossRef
3.
4.
Popadic S, Nikolic M. Pustular psoriasis in childhood and adolescence: a 20-year single-center experience. Pediatr Dermatol. 2014;31(5):575–9.PubMedCrossRef
5.
Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Koks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–9.PubMedCrossRef
6.
Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckland, NZ). 2016;6:131–44.
7.
Sticherling M, Augustin M, Boehncke W-H, Christophers E, Domm S, Gollnick H, et al. Therapy of psoriasis in childhood and adolescence—a German expert consensus. J Dtsch Dermatol Ges. 2011;9(10):815–23.PubMed
8.
Kosumi H, Ito T, Fujita Y, Izumi K, Maya Y, Yanagi T, et al. Generalized pustular psoriasis. J Pediatr. 2017;188:305.e1.CrossRef
9.
Haug V, Benoit S, Wohlleben M, Hamm H. Annular pustular psoriasis in a 14-month-old girl: a therapeutic challenge. J Dermatol Treat. 2017;28(6):520–2.CrossRef
10.
Zelickson BD, Muller SA. Generalized pustular psoriasis in childhood: report of thirteen cases. J Am Acad Dermatol. 1991;24(2 Part 1):186–94.PubMedCrossRef
11.
Olazagasti JM, Ma JE, Wetter DA. Clinical features, etiologic factors, associated disorders, and treatment of palmoplantar pustulosis: the Mayo Clinic Experience, 1996–2013. Mayo Clin Proc. 2017;92(9):1351–8.PubMedCrossRef
12.
Adışen E, Tekin O, Gülekon A, Gürer M. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009;23(7):814–9.PubMedCrossRef
13.
Sehgal VN, Verma P, Sharma S, Srivastava G, Aggarwal AK, Rasool F, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50(10):1195–211.PubMedCrossRef
14.
Ceovic R, Pasic A, Lipozencic J, Murat-Susic S, Skerlev M, Husar K, et al. Treatment of childhood psoriasis. Acta Dermatovenerol Croat. 2006;14(4):261–4.PubMed
15.
Umezawa Y, Mabuch T, Ozawa A. Generalized pustular psoriasis in a child: observation of long-term combination therapy with etretinate and calcipotriol for 16 years. Pediatr Dermatol. 2012;29(2):206–8.PubMedCrossRef
16.
Georgala S, Rigopoulos D, Aroni K, Stratigos JT. Generalized pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol. 1994;33(7):515–6.PubMedCrossRef
17.
Liang CY, Lin TY, Lin YK. Successful treatment of pediatric nail psoriasis with periodic pustular eruption using topical indigo naturalis oil extract. Pediatr Dermatol. 2013;30(1):117–9.PubMedCrossRef
18.
Poddighe D, Brazzelli V, Licari A, Marseglia GL. Acute pustular dermatosis, following topical treatment with pimecrolimus, in a child affected with atopic and contact hand dermatitis. J Pediatr Pharmacol Ther. 2016;21(1):81–4.PubMedPubMedCentral
19.
Balato A, Scalvenzi M, Cirillo T, Gallo L, Ayala F, Balato N. Psoriasis in children: a review. Curr Pediatr Rev. 2015;11(1):10–26.PubMedCrossRef
20.
Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–70.PubMedCrossRef
21.
Mizuno N, Uematsu S, Ono M. Pustular psoriasis (Zumbusch) treated with 8-methoxypsoralen phototherapy. Nihon Hifuka Gakkai Zasshi. 1975;85(10):587–94.PubMed
22.
Lee W-K, Kim J-M, Kim G-W, Kim H-S, Kim B-S, Kim M-B, et al. Recalcitrant infantile generalized pustular psoriasis successfully treated with acitretin and narrowband ultraviolet B. J Dermatol. 2018;45(3):330–1.PubMedCrossRef
23.
Kopp T, Karlhofer F, Szépfalusi Z, Schneeberger A, Stingl G, Tanew A. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004;151(4):912–6.PubMedCrossRef
24.
Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23(3):306–8.PubMedCrossRef
25.
Mazzatenta C, Martini P, Luti L, Domenici R. Diffuse sterile pustular eruption with changing clinical features in a 2-year old. Pediatr Dermatol. 2005;22(3):250–3.PubMedCrossRef
26.
Lara-Corrales I, Ramnarine S, Lansang P. Treatment of childhood psoriasis with phototherapy and photochemotherapy. Clin Med Insights Pediatr. 2013;7:25–33.PubMedPubMedCentral
27.
28.
29.
Saikaly SK, Mattes M. Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend. Cureus. 2016;8(6):e652.PubMedPubMedCentral
30.
Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl 1):S43–54.PubMedCrossRef
31.
Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321–34.PubMedCrossRef
32.
Morita A, Yamazaki F, Matsuyama T, Takahashi K, Arai S, Asahina A, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371–80.PubMedPubMedCentralCrossRef
33.
Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–7.PubMedCrossRef
34.
Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325–32.PubMedCrossRef
35.
Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Group JBS. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–51.PubMedCrossRef
36.
Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–19.PubMedCrossRef
37.
Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–94.PubMedPubMedCentralCrossRef
38.
Ollech A, Zvulunov A, Pavlovsky L, Hodak E, Ben-Amitai D. Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center. J Dermatol Treat. 2019;30(2):152–5.CrossRef
39.
Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88.PubMedCrossRef
40.
Subedi S, Yu Q, Chen Z, Shi Y. Management of pediatric psoriasis with acitretin: a review. Dermatol Ther. 2018;31:e12571.CrossRef
41.
Chen P, Li C, Xue R, Chen H, Tian X, Zeng K, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatol Treat. 2018;29(4):353–63.CrossRef
42.
Gautam M, Tahiliani H, Nadkarni N, Patil S, Godse K. Acitretin in pediatric dermatoses. Indian J Paediatr Dermatol. 2016;17(2):87–94.CrossRef
43.
Posso-De Los Rios CJ, Pope E, Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31(4):430–9.PubMedCrossRef
44.
Pilkington T, Brogden RN. Acitretin: a review of its pharmacology and therapeutic use. Drugs. 1992;43(4):597–627.PubMedCrossRef
45.
Sbidian E, Maza A, Montaudié H, Gallini A, Aractingi S, Aubin F, et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. J Eur Acad Dermatol Venereol. 2011;25(s2):28–33.PubMedCrossRef
46.
Wang Y, Cheng R, Lu Z, Guo Y, Yan M, Liang J, et al. Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes. J Dermatol Sci. 2017;85(3):235–40.PubMedCrossRef
47.
Inaloz HS. A case of childhood generalized pustular psoriasis successfully treated with a combination of acitretin and cyclosporine. Pediatr Dermatol. 2017;34:S48.
48.
49.
Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, et al. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther (Heidelb). 2016;6(2):125–42.PubMedPubMedCentralCrossRef
50.
Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003;49(2):171–82 (quiz 83-6).PubMedCrossRef
51.
Glover MT, Peters AM, Atherton DJ. Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol. 1987;116(5):609–14.PubMedCrossRef
52.
Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf. 2005;4(1):129–38.PubMedCrossRef
53.
Georgakopoulos JR, Ighani A, Yeung J. Short- and long-term management of an acute pustular psoriasis flare: a case report. J Cutan Med Surg. 2017;21(5):452–6.PubMedCrossRef
54.
Kilic SS, Hacimustafaoglu M, Celebi S, Karadeniz A, Ildirim I. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–8.PubMedCrossRef
55.
Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat. 2003;14(2):113–8.CrossRef
56.
Bulbul Baskan E, Yazici S, Tunali S, Saricaoglu H. Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis. J Dermatol Treat. 2016;27(4):328–31.CrossRef
57.
Dogra S, Mahajan R, Narang T, Handa S. Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review. J Dermatol Treat. 2017;28(1):18–20.CrossRef
58.
Georgesen C, Wildman H, Wang X, Magro C. Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: a treatment approach. Dermatol Online J. 2017;23(11):14.
59.
Erkko P, Granlund H, Remitz A, Rosen K, Mobacken H, Lindelof B, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol. 1998;139(6):997–1004.PubMedCrossRef
60.
Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3 Part 2):S25–8.PubMedCrossRef
61.
Xiao T, Li B, He C-D, Chen H-D. Juvenile generalized pustular psoriasis. J Dermatol. 2007;34(8):573–6.PubMedCrossRef
62.
Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol. 2018;16(1):46.CrossRef
63.
Dogra S, Kumaran MS, Handa S, Kanwar AJ. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol. 2005;22(1):85–6.PubMedCrossRef
64.
Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis: response to methotrexate. Skinmed. 2011;9(3):190–1.PubMed
65.
Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–37.PubMedCrossRef
66.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.PubMedCrossRef
67.
Jeon C, Nakamura M, Sekhon S, Yan D, Wu JJ, Liao W, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Rep. 2017;3(6):495–7.PubMedPubMedCentralCrossRef
68.
Eto A, Nakao M, Furue M. Three cases of palmoplantar pustulosis successfully treated with apremilast. J Dermatol. 2019;46(1):e29–30.PubMedCrossRef
69.
Adamo S, Nilsson J, Krebs A, Steiner U, Cozzio A, French LE, et al. Successful treatment of SAPHO syndrome with apremilast. Br J Dermatol. 2018;179(4):959–62.PubMedCrossRef
70.
Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol. 2017;42(4):471–3.PubMedCrossRef
71.
Kromer C, Wilsmann-Theis D, Gerdes S, Philipp S, Schaarschmidt ML, Schmieder A, et al. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges. 2019;17(5):503–16.PubMedPubMedCentral
72.
Cordoro KM, Ucmak D, Hitraya-Low M, Rosenblum MD, Liao W. Response to interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA). JAMA Dermatol. 2017;153(1):106–8.PubMedCrossRef
73.
Vergou T, Moustou AE, Sfikakis PP, Antoniou C, Stratigos AJ. Pharmacodynamics of TNF-alpha inhibitors in psoriasis. Expert Rev Clin Pharmacol. 2011;4(4):515–23.PubMedCrossRef
74.
Fialova J, Vojackova N, Vanousova D, Hercogova J. Juvenile generalized pustular psoriasis treated with etanercept. Dermatol Ther. 2014;27(2):105–8.PubMedCrossRef
75.
Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology. 2006;213(4):350–2.PubMedCrossRef
76.
Mazzotta A, Saraceno R, Esposito M, Chimenti S. Etanercept, childhood and long-term safety: a case of 5 years treatment. Eur J Dermatol. 2011;21(5):776–7.PubMedCrossRef
77.
Cuperus E, Koevoets R, van der Smagt JJ, Toonstra J, de Graaf M, Frenkel J, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T > C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin. JAAD Case Rep. 2018;4(2):192-5.
78.
Babuna Kobaner G, Polat Ekinci A, Yilmaz Z, Sun GP. A challenging pediatric case of generalized pustular psoriasis: successful treatment with sequential use of infliximab and etanercept. Pediatr Dermatol. 2017;34:S51.CrossRef
79.
Silpa-archa N, Wongpraparut C. A recalcitrant acrodermatitis continua of Hallopeau successfully treated with etanercept. J Med Assoc Thai. 2011;94(9):1154–7.PubMed
80.
Floristan U, Feltes R, RamÍRez P, Alonso ML, De Lucas R. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol. 2011;28(3):349–50.PubMedCrossRef
81.
Marji JS, Marcus R, Moennich J, Mackay-Wiggan J. Use of biologic agents in pediatric psoriasis. J Drugs Dermatol. 2010;9(8):975–86.PubMed
82.
Luu M, Cordoro KM. The evolving role of biologics in the treatment of pediatric psoriasis. Skin Ther Lett. 2013;18(2):1–4.
83.
Pan J, Qiu L, Xiao T, Chen HD. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab. Dermatol Ther. 2016;29(3):164–7.PubMedCrossRef
84.
Glerup M, Veirum J, Iversen L, Christiansen M, Herlin T. Generalized pustular psoriasis in infant with heterozygous mutation in the IL36RN gene successfully treated with infliximab. Pediatr Rheumatol. 2014;12(Suppl 1):79.CrossRef
85.
Lee ES, Jang YH. A single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of childhood. J Dermatol. 2010;37:124.
86.
Tsang V, Dvorakova V, Enright F, Murphy M, Gleeson C. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30(11):e117–9.PubMed
87.
Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol. 2010;27(5):539–40.PubMedCrossRef
88.
Skrabl-Baumgartner A, Weger W, Salmhofer W, Jahnel J. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 2015;32(1):e13–4.PubMedCrossRef
89.
Zhou LL, Georgakopoulos JR, Ighani A, Yeung J. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;22(6):591–601.PubMedCrossRef
90.
Schwartz G, Paller AS. Targeted therapies for pediatric psoriasis. Semin Cutan Med Surg. 2018;37(3):167–72.PubMedCrossRef
91.
Alvarez AC, Rodriguez-Nevado I, De Argila D, Rubio FP, Rovira I, Torrelo A, et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol. 2011;28(2):195–7.PubMedCrossRef
92.
Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat. 2005;16(5–6):350–2.CrossRef
93.
Mohandas P, Browne R, Srinivasan J, Murphy R, Kulkarni K, Ravenscroft J. Acute generalized pustular eruption in a young girl: a diagnostic and therapeutic challenge. Br J Dermatol. 2018;178(4):e290–1.
94.
Arteaga-Henriquez M, Latour-Alvarez I, Morel LN, Zamberk P, Martin-Davila F, Hernandez-Martin A, et al. Generalized pustular psoriasis in an infant: response to adalimumab. Pediatr Dermatol. 2019;36:S41.
95.
Capusan TM, Herrero-Moyano M, Martínez-Mera C, De Argila D, Chaves A, Rodriguez Nevado I, et al. Combined therapy in 2 cases of pustular generalized psoriasis with IL36RN gene mutations. Pediatr Dermatol. 2017;34:S46.CrossRef
96.
Matsumoto A, Komine M, Karakawa M, Kishimoto M, Ohtsuki M. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017;44(2):202–4.PubMedCrossRef
97.
Shelling ML, Vitiello M, Lanuti EL, Miteva M, Romanelli P, Kerdel FA. A case of palmoplantar pustulosis induced by certolizumab pegol: new anti-TNF-alpha demonstrates the same class effect. J Clin Aesthet Dermatol. 2012;5(8):40–1.PubMedPubMedCentral
98.
Koizumi H, Tokuriki A, Oyama N, Ido H, Sugiura K, Akiyama M, et al. Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis. J Dermatol. 2017;44(6):723–4.PubMedCrossRef
99.
Hess S, Hospach T, Nossal R, Dannecker G, Magdorf K, Uhlemann F. Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. Eur J Pediatr. 2011;170(10):1337–42.PubMedCrossRef
100.
Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36(5):1185–206.PubMedCrossRef
101.
Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G, et al. Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo. 2006;58(1):31–8.PubMed
102.
Chen W, Peng C, Ding Y, Yi X, Gao Y. Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: a case report. Dermatol Ther. 2019;32(2):e12838.PubMedCrossRef
103.
Behera SK, Selvarajan S, Mathews J, Shajil C, Das S, Munisamy M, et al. A novel desensitization protocol for infliximab hypersensitivity in a 13-year old patient with pustular psoriasis. Curr Drug Saf. 2019;14(2):158–62.PubMedCrossRef
104.
Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol. 2016;9(6 Suppl 1):S12–6.PubMedPubMedCentral
105.
Galluzzo M, D’Adamio S, Teoli M, Bianchi L, Talamonti M. Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019;32(3):e12899.PubMedPubMedCentral
106.
Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work. J Dermatol. 2018;45(11):1353–6.PubMedCrossRef
107.
Kostner K, Prelog M, Almanzar G, Fesq H, Haas JP, Hugle B. Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology (Oxford). 2018;57(5):936–8.CrossRef
108.
Molho-Pessach V, Alyan R, Gordon D, Jaradat H, Zlotogorski A. Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent. JAMA Dermatol. 2017;153(5):473–5.PubMedCrossRef
109.
Levin EC, Debbaneh M, Koo J, Liao W. Biologic therapy in erythrodermic and pustular psoriasis. J Drugs Dermatol. 2014;13(3):342–54.PubMed
110.
Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12–17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.PubMedCrossRef
111.
Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, García-Díez A. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol. 2010;163(6):1346–7.PubMedCrossRef
112.
Schnabel V, Broekaert SMC, Schon MP, Mossner R. Clearance of annular pustular psoriasis with ustekinumab. Eur J Dermatol. 2017;27(3):296–7.PubMedCrossRef
113.
Cherqaoui B, Rossi-Semerano L, Piram M, Koné-Paut I. Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist. Ann Rheum Dis. 2018;77(12):e89.CrossRef
114.
Herlin T, Christiansen M, Jørgensen SE, Høst C, Glerup M, Veirum JE, et al. Long-term treatment with ustekinumab for generalized pustular psoriasis in a child with heterozygous mutation in the IL36RN and TYK2 gene. Pediatr Rheumatol. 2019;17(Suppl 1):P1092.
115.
Habal N, Chen Y, Jordan C, Liu Y, Neal DCC, Stone D, et al. Pathogenesis study of infantile-onset, severe pustular psoriasis reveals a de novo mutation in CARD14 causing psoriasis which responds clinically to IL-12/23 blocking treatment with ustekinumab. Arthritis Rheum. 2011;63(10):S116.
116.
Bohdanowicz M, Sajic D. Refractory palmoplantar pustular psoriasis treated with high-dose ustekinumab after initial failure. J Cutan Med Surg. 2019;23(1):102–4.PubMedCrossRef
117.
Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–9.PubMedPubMedCentralCrossRef
118.
Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–39.PubMedPubMedCentralCrossRef
119.
Khatri A, Eckert D, Oberoi R, Suleiman A, Pang Y, Cheng L, et al. Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis. J Clin Pharmacol. 2019;59(12):1656–68.PubMedPubMedCentralCrossRef
120.
Cornelius V, Wilson R, Cro S, Barker J, Burden D, Griffiths CEM, et al. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials. 2018;19(1):465.PubMedPubMedCentralCrossRef
121.
Zaouak A, Magdoud O, Ben Jannet S, Hammami H, Fenniche S. Pediatric generalized pustular psoriasis: a severe skin condition. J Eur Acad Dermatol Venereol. 2019;33:68.
122.
Ismail D, Madhwapathi V, Yoo J, Madhogaria S, Ogboli M, Stewart G. Infantile generalized pustular psoriasis and its differential diagnosis. Br J Dermatol. 2016;175:169–70.
123.
Tay Y-K, Tham S-N. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J Dermatol. 1997;36(4):266–71.PubMedCrossRef
124.
Yasuda E, Yokota K, Hirayama K, Kiyokane K. Generalized pustular psoriasis of childhood; a case report. Skin Res. 1994;36(5):641–8.
125.
Nazarian RS, Nia J, Geller L. Pustular psoriasis in an adolescent: a diagnostic and therapeutic challenge. J Am Acad Dermatol. 2019;81(4 Supplement 1):AB260.
126.
Bonekamp N, Caorsi R, Viglizzo GM, Graaf M, Minoia F, Grossi A, et al. High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA). Ann Rheum Dis. 2018;77(8):1241.PubMed
127.
Rossi-Semerano L, Piram M, Chiaverini C, De Ricaud D, Smahi A, Koné-Paut I. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics. 2013;132(4):e1043.PubMedCrossRef
128.
Zhang X, Liang J, Li C. Investigation of the efficacy and safety of acitretin treatment in children with pustular psoriasis. Br J Dermatol. 2017;177(5):e272.
129.
Wang Q, Zhang L, Liu W. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China. An Bras Dermatol. 2017;92(3):319–22.PubMedPubMedCentralCrossRef
130.
Ying MNS, Aan MJ. Report of 3 cases of Juvenile generalized pustular psoriasis—a rare disease of this age group. J Am Acad Dermatol. 2016;74(5):AB216.
131.
Charbit L, Mahé E, Phan A, Chiaverini C, Boralevi F, Bourrat E, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174(5):1118–21.PubMedCrossRef
132.
Volc-Platzer B, Gruber R, Rainer G. Pustular psoriasis and palmoplantar keratoderma (PPK) with features of ectodermal dysplasia and mutation in the plakin domain of the desmoplakin gene-a new entity or mere coincidence? Pediatr Dermatol. 2016;33:S28.CrossRef
133.
Ellingford JM, Black GCM, Clayton TH, Judge M, Griffiths CEM, Warren RB. A novel mutation in IL36RN underpins childhood pustular dermatosis. J Eur Acad Dermatol Venereol. 2016;30(2):302–5.PubMedCrossRef
134.
Liao PB, Rubinson R, Howard R, Sanchez G, Frieden IJ. Annular pustular psoriasis—most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002;19(1):19–25.PubMedCrossRef
135.
George L, Mathews V, George B, Thomas M, Pulimood SA. Generalized pustular psoriasis following allogeneic stem cell transplantation. Clin Exp Dermatol. 2015;40(2):160–2.PubMedCrossRef
136.
Benoit S, Wobser M, Hamm H. Therapeutic challenge: annular pustular psoriasis in a 14-month-old girl. J Dtsch Dermatol Ges. 2014;12:38.
137.
Bayram FE, Karagenç Y. Successful use of acitretin in combination with narrowband ultraviolet B phototherapy in a child with pustular psoriasis. J Dtsch Dermatol Ges. 2014;12:36.CrossRef
138.
Uçmak D, Akkurt ZM, Türkçü G, Acar G, Akdeniz S, Arica M. Generalized pustular psoriasis in two children: acitretin therapy: case report. Turk Klin Tip Bilim. 2014;24(1):24–8.
139.
Namba C, Murakami M, Hanakawa Y, Tohyama M, Shirakata Y, Tauchi H, et al. Infantile generalized pustular psoriasis: successful disease control with intermittent etretinate. J Dermatol. 2014;41(5):403–6.PubMedCrossRef
140.
Yu Q, Zhang TM, Liu Q, Gu J, Bi XL. A case of pustular psoriasis with Intercellular epidermal deposits of IgA and IgM. J Clin Dermatol. 2013;42(9):544–7.
141.
Lu ZY, Zhang H, Guo YF, Yu H, Cheng RH, Tao JF, et al. Efficacy and safety of low-dose acitretin therapy for childhood generalized pustular psoriasis: report of 29 cases from China. J Dermatol. 2012;39:237.
142.
Park SY, Kim JY, Choi M, Cho KH. A case of pustular psoriasis developed during infliximab treatment for Crohn disease. J Dermatol. 2012;39:240.
143.
Jesus AA, Osman M, Silva CA, Kim PW, Pham TH, Gadina M, et al. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 2011;63(12):4007–17.PubMedPubMedCentralCrossRef
144.
De Oliveira ST, Maragno L, Arnone M, Takahashi MDF, Romiti R. Generalized pustular psoriasis in childhood. Pediatr Dermatol. 2010;27(4):349–54.PubMedCrossRef
145.
Zribi J, Mseddi M, Marrekchi S, Elleuch N, Masmoudi A, Meziou TJ, et al. Familial childhood pustular psoriasis. J Eur Acad Dermatol Venereol. 2010;24:76.CrossRef
146.
Zribi J, Mseddi M, Marrekchi S, Abdelmaksoud W, Elleuch N, Meziou TJ, et al. Generalized pustular psoriasis in an infant. J Eur Acad Dermatol Venereol. 2010;24:33.CrossRef
147.
Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352–4.PubMedCrossRef
148.
Ergin S, Ersoy-Evans S, Şahin S, Özkaya Ö. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatol Treat. 2008;19(6):341–3.CrossRef
149.
Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol. 2007;24(5):563–4.PubMedCrossRef
150.
Benoit C, Young P, Courville PH, Mallet E, Joly P. Generalized pustular psoriasis of children and retinoids. Nouv Dermatol. 2001;20(3):213.
151.
Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol. 1998;15(2):144–6.PubMedCrossRef
152.
Prose NS, Fahrner LJ, Miller CR, Layfield L. Pustular psoriasis with chronic recurrent multifocal osteomyelitis and spontaneous fractures. J Am Acad Dermatol. 1994;31(2 II):376–9.PubMedCrossRef
153.
Judge MR, McDonald A, Black MM. Pustular psoriasis in childhood. Clin Exp Dermatol. 1993;18(2):97–9.PubMedCrossRef
154.
Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalized pustular psoriasis in children. Arch Dermatol. 1987;123(2):230–3.PubMedCrossRef
155.
156.
Karamfilov T, Wollina U. Juvenile generalized pustular psoriasis. Acta Derm Venereol. 1998;78(3):220.PubMedCrossRef
157.
Rosinska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266–72.PubMedCrossRef
158.
Paik JH, Park PS, Choi YJ, Sung HS. Juvenile generalized pustular psoriasis treated with etretinate and methotrexate. Korean J Dermatol. 1989;27(1):64–8.
159.
Wakelin SH, Emmerson RW. Excess granulation tissue development during treatment with cyclosporin. Br J Dermatol. 1994;131(1):147–8.PubMedCrossRef
160.
Sözeri B, Gerçeker-Türk B, Yıldız-Atıkan B, Mir S, Berdeli A. A novel mutation of interleukin-1 receptor antagonist (IL1RN) in a DIRA patient from Turkey: diagnosis and treatment. Turk J Pediatr. 2018;60(5):588–92.PubMedCrossRef
161.
Caorsi R, Minoia F, Viglizzo G, Grossi A, Chiesa S, Picco P, et al. The therapeutic challenge of DITRA syndrome. Pediatr Rheumatol. 2017;15(Suppl 1):44.
162.
Rajendra B. Pustular psoriasis in a child. Cogent Med. 2016;3:1.
163.
Arostegui JI, Vicente-Villa MA, Chaves A, Gonzalez-Roca E, Ruiz-Ortiz E, Rius J, et al. P02-002-IL36RN mutations in patients with DITRA. Pediatr Rheumatol. 2013;11(Suppl 1):A109.CrossRef
164.
Kluger N, Bessis D, Guillot B, Girard C. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis). J Am Acad Dermatol. 2011;64(6):1154–8.PubMedCrossRef
165.
Antunes J, André M, Filipe P. Recurrent childhood von Zumbusch pustular psoriasis associated with neutrophilic cholangitis, successfully controlled with etanercept. J Am Acad Dermatol. 2010;62(3):AB128.
166.
Mosca A, Souza C, Moraes G, Carvalho P. Von Zumbush psoriasis: a rare form in childhood. J Am Acad Dermatol. 2010;62(3):AB137.
167.
Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154(1):181–3.PubMedCrossRef
168.
Kiszewski AE, De Villa D, Scheibel I, Ricachnevsky N. An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy. Pediatr Dermatol. 2009;26(1):105–6.PubMedCrossRef
169.
Stephenson CM, Prajapati V, Miettunen PM. Effective treatment of severe juvenile pustular psoriasis with cyclosporine and etanercept: a case report utilizing autoinflammatory diseases activity index (AIDAI) to document treatment response. Pediatr Rheumatol. 2017;15(Suppl 1):37.
170.
Alli N, Güngör E, Karakayali G, Lenk N, Artüz F. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139(4):754–5.PubMedCrossRef
171.
Wollina U, Fünfstück V. Juvenile generalized circinate pustular psoriasis treated with oral cyclosporin A. Eur J Dermatol. 2001;11(2):117–9.PubMed
172.
Kobayashi A, Ogawa E, Matsuzaki S, Minagawa A, Okuyama R. Pediatric case of generalized pustular psoriasis developing acute pancreatitis. J Dermatol. 2018;45(10):e278–9.PubMedCrossRef
173.
Takahashi M, Takeuchi M, Matsunaga K. Infant with generalized pustular psoriasis who responded to cyclosporin A therapy. J Dermatol. 2015;42(9):911–3.PubMedCrossRef
174.
Sugiura K, Uchiyama R, Okuyama R, Akiyama M. Varicella zoster virus-associated generalized pustular psoriasis in a baby with heterozygous IL36RN mutation. J Am Acad Dermatol. 2014;71(5):e216–8.PubMedCrossRef
175.
Liu L, Tan Q, Wang G. Treatments for juvenile generalized pustular psoriasis. J Dermatol. 2012;39:232.CrossRef
176.
Nakamura S, Hashimoto Y, Igawa S, Kajino M, Nishi K, Takahashi H, et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol. 2009;34(8):e1023–4.PubMedCrossRef
177.
Mahé E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. JAMA Dermatol. 2001;137(11):1532–3.
178.
Koike Y, Okubo M, Kiyohara T, Fukuchi R, Sato Y, Kuwatsuka S, et al. Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation of IL36RN. Br J Dermatol. 2017;177(6):1732–6.PubMedCrossRef
179.
Miyake T, Umemura H, Doi H, Kousogabe J, Tsuji K, Hamada T, et al. Annular pustular psoriasis with a heterozygous IL36RN mutation. Eur J Dermatol. 2015;25(4):349–50.PubMedCrossRef
180.
Renert-Yuval Y, Horev L, Babay S, Tams S, Ramot Y, Zlotogorski A, et al. IL36RN mutation causing generalized pustular psoriasis in a Palestinian patient. Int J Dermatol. 2014;53(7):866–8.PubMedCrossRef
181.
Dini V, Barbanera S, Romanelli M. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Derm Venereol. 2013;93(5):588–9.PubMedCrossRef
182.
183.
Lim TM, Birchall N, Purvis D, Rowan D, Chan WC, Agnew K. Pustular psoriasis in early childhood. Australas J Dermatol. 2012;53(4):A2.CrossRef
184.
Weishaupt C, Metze D, Luger TA, Ständer S. Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges. 2007;5(5):397–400.PubMedCrossRef
185.
Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271–3.PubMedCrossRef
186.
Nakouri I, Jaber K, Litaiem N, Youssef S, Dhaoui MR, Doss N. Treatment of severe pediatric psoriasis by methotrexate: report of six cases. J Eur Acad Dermatol Venereol. 2016;30:28–9.
187.
Nakouri I, Jaber K, Litaiem N, Youssef S, Dhaoui MR, Doss N. Infantile annular pustular psoriasis: a case report. J Eur Acad Dermatol Venereol. 2016;30:29.CrossRef
188.
Fitas AL, Brissos J, Conde M, Freitas IC, Abranches M, Sassetti L. Pustular psoriasis, severe hypocalcemia and albright phenotype—assembling the pieces of the puzzle. Acta Paediatr. 2010;99:56.
189.
190.
Hubler WR Jr. Familial juvenile generalized pustular psoriasis. Arch Dermatol. 1984;120(9):1174–8.PubMedCrossRef
191.
Khan SA, Peterkin GA, Mitchell PC. Juvenile generalized pustular psoriasis. A report of five cases and a review of the literature. Arch Dermatol. 1972;105(1):67–72.PubMedCrossRef
192.
Henriksen L, Zachariae H. Pustular psoriasis and arthritis in congenital psoriasiform erythroderma. Dermatologica. 1972;144(1):12–8.PubMedCrossRef
193.
Marrani E, Belli G, Simonini G, Trapani S, Caproni M, Lionetti P. SAPHO syndrome in pediatric patients with inflammatory bowel disease treated with infliximab. Dig Liver Dis. 2018;50(11):1249–51.PubMedCrossRef
194.
Maccora I, Tirelli F, Marrani E, Giani T, Simonini G, Cimaz R. SAPHO syndrome in adolescents: a case series. Pediatr Rheumatol. 2018;16(Suppl 2):P318.
195.
da Silva PCG, de Oliveira EF, Goldenzon AV, da Silva PCG, Rodrigues MCF. Challenges in diagnosis and treatment of a case of SAPHO syndrome in childhood. An Bras Dermatol. 2011;86(4 suppl. 1):46–9.CrossRef
196.
Farooq M, Nakai H, Fujimoto A, Fujikawa H, Matsuyama A, Kariya N, et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum Mutat. 2013;34(1):176–83.PubMedCrossRef
197.
Topkarci Z, Kilic MP, Erdogan B. Nose sign in a child with pustular psoriasis. Pediatr Dermatol. 2017;34:S197.CrossRef
198.
Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253–60.PubMedCrossRef
Metadata
Title
Pharmacological Management of Pediatric Pustular Psoriasis
Authors
Yi-Wei Huang
Tsen-Fang Tsai
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 3/2020
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-020-00383-6

Other articles of this Issue 3/2020

Pediatric Drugs 3/2020 Go to the issue

Original Research Article

The Role of Oral Administration of Immunoglobulin in Managing Diarrheal Illness in Immunocompromised Children

Commentary

Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy

Original Research Article

A Prospective Cohort Study of Factors Associated with Empiric Antibiotic De-escalation in Neonates Suspected with Early Onset Sepsis (EOS)

Current Opinion

Why and How Should We Treat Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome?

Review Article

Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review

Original Research Article

Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group